MIND-NRG
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
MIND-NRG
Industry:
Biotechnology Medical Device Neuroscience
Founded:
2010-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.mind-nrg.com
Total Employee:
1+
Status:
Closed
Contact:
41 22 737 00 00
Email Addresses:
[email protected]
Total Funding:
23.7 M USD
Current Employees Featured
Founder
Investors List
Limburgse Reconversie Maatschappij
Limburgse Reconversie Maatschappij investment in Series B - Mind-NRG
Index Ventures
Index Ventures investment in Series B - Mind-NRG
Index Ventures
Index Ventures investment in Series A - Mind-NRG
Index Ventures
Index Ventures investment in Series A - Mind-NRG
